Drug Trial Radar · NCT00940420
A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C
Last checked: Nov 20, 2026Latest source record: Nov 2, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,695
Actual
Start
Oct 2002
Primary completion
Nov 2009
Study completion Nov 2009
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jul 16, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This 2 arm open-label study will assess the safety and tolerability of combination treatment with Peginterferon alfa (Pegasys) and Ribavirin (Copegus) in patients with chronic hepatitis C. Patients will be assigned to receive Peginterferon alfa (Pegasys) 180 mcg sc once a week and Ribavirin (Copegus) 800 - 1200 mg po daily for either 24 or 48 weeks. Allocation to the treatment arms is to the discretion of the investigator (mainly according to genotype). Adverse events will be monitored throughout the study and hematologic parameters every 2 weeks and twice during the 24-week follow-up.
Conditions
- Hepatitis C, Chronic
Interventions
Copegus (ribavirin)Drug
800 - 1200 mg po daily for 24 weeks
Copegus (ribavirin)Drug
800 - 1200 mg po daily for 48 weeks
peginterferon alfa-2a [Pegasys]Drug
180 mcg sc once weekly for 24 weeks
peginterferon alfa-2a [Pegasys]Drug
180 mcg sc once weekly for 48 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- safety and tolerability with regard to clinical AEs and laboratory parametersTime frame: assessed every 2 weeks throughout study and after 8 weeks follow-up
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Afula, Israel
Site not named
Ashkelon, Israel
Site not named
Bat Yam, Israel
Site not named
Beersheba, Israel
Site not named
Hadera, Israel
Site not named
Haifa, Israel
Site not named
Haifa, Israel
Site not named
Haifa, Israel
Site not named
Holon, Israel
Site not named
Jerusalem, Israel
Site not named
Kfar Saba, Israel
Site not named
Nahariya, Israel
Site not named
Nazareth, Israel
Site not named
Petah Tikva, Israel
Site not named
Petah Tikva, Israel
Site not named
Ramat Gan, Israel
Site not named
Rehovot, Israel
Site not named
Safed, Israel
Site not named
Tel Aviv, Israel
Site not named
Tsrifin, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.